NASDAQ$SGMO
Sangamo Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Sangamo Therapeutics reported a net loss of $31.0 million for Q1 2026 amid ongoing liquidity challenges.
Sangamo Therapeutics Inc. recorded revenues of $1.4 million and a net loss of $31.0 million for the first quarter of 2026. The company highlighted substantial doubt about its ability to continue as a going concern and the need for immediate additional financing. Cash and cash equivalents stood at $27.6 million at quarter end.
- Q1 2026 revenues totaled $1.4 million, down from $6.4 million in Q1 2025.
- Net loss was $31.0 million with basic and diluted EPS of $(0.08).
- Cash position improved to $27.6 million following equity raises but remains limited.
- Company faces delisting from Nasdaq and is exploring strategic alternatives due to funding needs.
Headline financials
Revenue & EPS history
Sangamo · Revenue · Quarterly
$1.44M
Forward guidance
Management emphasized the urgent need for substantial additional capital through partnerships or financing to continue operations beyond Q3 2026, with risks of scaling back or ceasing operations.
Tailwinds
- Progress on Fabry BLA submission and neurology preclinical programs
- New research agreement with Lilly for capsid platform
Headwinds
- Substantial doubt on going concern status
- Nasdaq delisting and OTCQB trading transition
- Limited cash runway into Q3 2026 without new funding
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
+0.0%
Avg return
Earnings day
+1.7%
Avg return
5 days after
-5.1%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+59.1%
Q1 2017
Best reaction
-39.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.4% | -5.0% | — | |
| Q4 2025 | -1.3% | -3.2% | -61.3% | |
| Q3 2025 | -16.1% | -9.1% | -9.1% | |
| Q2 2025 | -5.6% | +12.5% | +14.6% | |
| Q1 2025 | -39.1% | -37.3% | -33.3% | |
| Q4 2024 | -16.2% | -13.9% | -29.7% | |
| Q3 2024 | -9.6% | -24.1% | -29.3% | |
| Q2 2024 | +11.6% | +32.5% | -2.6% | |
| Q1 2024 | +11.7% | +14.0% | +14.0% | |
| Q4 2023 | -9.4% | -1.2% | -37.2% | |
| Q3 2023 | -27.0% | -30.2% | -28.6% | |
| Q2 2023 | -10.3% | -7.7% | -18.8% | |
| Q1 2023 | -0.6% | -6.2% | -21.7% | |
| Q4 2022 | +2.8% | +4.2% | -41.5% | |
| Q3 2022 | -15.0% | -19.0% | -14.3% | |
| Q2 2022 | +8.3% | +9.2% | +15.2% | |
| Q1 2022 | -9.6% | -15.5% | -18.8% | |
| Q4 2021 | +9.7% | +9.3% | +6.9% | |
| Q3 2021 | +20.0% | +14.2% | -11.4% | |
| Q2 2021 | +3.2% | +7.0% | +6.6% | |
| Q1 2021 | -10.7% | -9.4% | -7.4% | |
| Q4 2020 | -9.2% | -2.8% | -2.7% | |
| Q3 2020 | +12.6% | +8.7% | -6.2% | |
| Q2 2020 | +2.4% | +9.1% | -12.3% | |
| Q1 2020 | +12.5% | +15.4% | +27.1% | |
| Q4 2019 | +27.5% | +21.9% | -4.9% | |
| Q3 2019 | -1.3% | +3.4% | +23.3% | |
| Q2 2019 | +1.1% | -5.2% | -10.3% | |
| Q1 2019 | -14.8% | -13.5% | -15.6% | |
| Q4 2018 | +7.8% | +8.2% | +2.4% | |
| Q3 2018 | -22.0% | -24.5% | -20.9% | |
| Q2 2018 | +8.9% | +13.2% | -2.1% | |
| Q1 2018 | -5.8% | -5.5% | +1.2% | |
| Q4 2017 | +12.4% | +5.6% | -2.0% | |
| Q3 2017 | +12.6% | +7.9% | +41.4% | |
| Q2 2017 | +9.2% | +33.3% | +54.6% | |
| Q1 2017 | +59.1% | +90.9% | +65.9% | |
| Q4 2016 | +9.3% | +10.5% | +9.3% | |
| Q3 2016 | +2.7% | -2.7% | -4.1% | |
| Q2 2016 | -26.0% | -26.9% | -34.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | -11.7% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | -17.4% | — | — | |
| Q1 2015 | +7.9% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2014 | +1.4% | — | — | |
| Q2 2014 | +4.4% | — | — | |
| Q1 2014 | -9.4% | — | — | |
| Q4 2013 | +3.5% | — | — | |
| Q3 2013 | +4.6% | — | — | |
| Q2 2013 | +2.9% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -2.6% | — | — | |
| Q2 2012 | -0.8% | — | — | |
| Q1 2012 | +5.1% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -7.1% | — | — | |
| Q1 2011 | +2.7% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q3 2010 | +2.9% | — | — | |
| Q2 2010 | -1.8% | — | — | |
| Q1 2010 | -12.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro